Requirement of BAX for TRAIL/Apo2L-induced apoptosis of colorectal cancers: synergism with sulindac-mediated inhibition of Bcl-x(L).
about
Sulindac enhances the killing of cancer cells exposed to oxidative stressPuma and Trail/Dr5 pathways control radiation-induced apoptosis in distinct populations of testicular progenitorsDirect Activation of Bax Protein for Cancer TherapyEndogenous Bak inhibitors Mcl-1 and Bcl-xL: differential impact on TRAIL resistance in Bax-deficient carcinoma.EGFR inhibitors sensitize non-small cell lung cancer cells to TRAIL-induced apoptosis.Synergism of CPT-11 and Apo2L/TRAIL against two differentially sensitive human colon tumor xenografts.Celastrol, a triterpene, enhances TRAIL-induced apoptosis through the down-regulation of cell survival proteins and up-regulation of death receptors.Adenylate kinase 3 sensitizes cells to cigarette smoke condensate vapor induced cisplatin resistanceTransduction of tumor necrosis factor-related apoptosis-inducing ligand into hematopoietic cells leads to inhibition of syngeneic tumor growth in vivo.Cell penetrating peptide inhibitors of nuclear factor-kappa B.Radiotherapy sensitization by tumor-specific TRAIL gene targeting improves survival of mice bearing human non-small cell lung cancer.Ursolic acid, a pentacyclin triterpene, potentiates TRAIL-induced apoptosis through p53-independent up-regulation of death receptors: evidence for the role of reactive oxygen species and JNKCombination treatment with TRA-8 anti death receptor 5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancerTopoisomerase I requirement for death receptor-induced apoptotic nuclear fission.Valproic acid, an antiepileptic drug with histone deacetylase inhibitory activity, potentiates the cytotoxic effect of Apo2L/TRAIL on cultured thoracic cancer cells through mitochondria-dependent caspase activation.Volatile anesthetics protect cancer cells against tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis via caveolinsHigh cell surface death receptor expression determines type I versus type II signalingApoptosis pathway of liver cells in chronic hepatitis.Studies on p53, BAX and Bcl-2 protein expression and microsatellite instability in stage III (UICC) colon cancer treated by adjuvant chemotherapy: major prognostic impact of proapoptotic BAX.Death receptor-induced activation of the Chk2- and histone H2AX-associated DNA damage response pathways.UVB upregulates the bax promoter in immortalized human keratinocytes via ROS induction of Id3.Sulindac activates NF-κB signaling in colon cancer cells.Journey of TRAIL from Bench to Bedside and its Potential Role in Immuno-Oncology.Alpha-tocopheryl succinate and TRAIL selectively synergise in induction of apoptosis in human malignant mesothelioma cellsInvolvement of protective autophagy in TRAIL resistance of apoptosis-defective tumor cells.Overexpression of Bax induces apoptosis and enhances drug sensitivity of hepatocellular cancer-9204 cells.Tumor necrosis factor alpha-induced apoptosis requires p73 and c-ABL activation downstream of RB degradationEffects of Recombinant Circularly Permuted Tumor Necrosis Factor (TNF)-Related Apoptosis-Inducing Ligand (TRAIL) (Recombinant Mutant Human TRAIL) in Combination with 5-Fluorouracil in Human Colorectal Cancer Cell Lines HCT116 and SW480.
P2860
Q28475579-D3B26F3C-8442-4DF8-A967-F6A373BCD6B8Q28749705-5A88BD3F-0A4A-401C-A650-B6DA4F6B572FQ30353924-D5EAED25-3B8D-40DA-ACEB-945F072B1C5AQ33544118-AD705F67-C867-48D1-B2B8-B8E682E2F587Q33574958-FE84588D-9EE4-425D-A5D0-6C8FADA6F77BQ33680928-7A9B41DD-5325-4DB2-9738-0F6B57215961Q33799792-291C24C4-C0E3-4C65-9952-16F239D203E7Q33941309-DA5981F6-6338-4722-B438-0BC9EDA98BA5Q34139621-3E72A3B9-AE5D-451F-BF89-6BE7D1B04F6DQ34289086-2294A589-4A13-4168-AA84-19A96C6B3F5EQ34313135-859EFBD9-BAB4-4F89-AFFA-47364AB9B879Q34568521-0155BC89-AE2A-4415-AF13-091322287D29Q34610496-C75D4596-8AE8-4A5E-BCD8-8F0CCC2E9764Q34786705-3D4E478E-21C7-4A1C-AE0C-C28CB5133A70Q35082212-6B2FB67F-E900-4901-9658-FDAF4CD68C02Q35183060-7DE1CB40-268D-433B-B628-D0D087510ABCQ35371553-F3B8DBAF-FEE2-45A6-8CD8-7B12B45F8D79Q36178145-239F8E99-713F-497B-BF6D-30B24943A258Q36610436-718A284F-D8F4-42D4-8065-F536CB5C8CC6Q37033587-E5D9FEBD-748C-4EA1-80AF-6BE98B920550Q37381007-7DD3EFE5-C31E-4721-A0D3-E4B52EA9F2F8Q37497981-FF55E540-6354-46AA-B4D8-4F64DF3DBCA4Q38557486-5F9BE225-2A51-4160-BC9A-199B40E4BFE3Q38798516-9019E5F0-FAFE-4F91-8EF8-7B55944CA9F6Q39680489-B3C106E4-2C4A-44A2-9452-84B85B7B3C6BQ40408250-50225E42-B742-4447-9854-1AE414CEF1D2Q40560434-89E1FC98-6DB7-49AA-BFC4-459E74F0553FQ55396225-17E13626-B804-467E-A23F-1CCC81C5B25C
P2860
Requirement of BAX for TRAIL/Apo2L-induced apoptosis of colorectal cancers: synergism with sulindac-mediated inhibition of Bcl-x(L).
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Requirement of BAX for TRAIL/A ...... c-mediated inhibition of Bcl-x
@nl
Requirement of BAX for TRAIL/A ...... diated inhibition of Bcl-x(L).
@en
type
label
Requirement of BAX for TRAIL/A ...... c-mediated inhibition of Bcl-x
@nl
Requirement of BAX for TRAIL/A ...... diated inhibition of Bcl-x(L).
@en
prefLabel
Requirement of BAX for TRAIL/A ...... c-mediated inhibition of Bcl-x
@nl
Requirement of BAX for TRAIL/A ...... diated inhibition of Bcl-x(L).
@en
P1433
P1476
Requirement of BAX for TRAIL/A ...... diated inhibition of Bcl-x(L).
@en
P2093
Rajani Ravi
P304
P407
P577
2002-03-01T00:00:00Z